Borrelia Burgdorferi Bacterin

Verify with FDA CVM →

475 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
475
Total Reports
13
Deaths Reported
270.0%
Death Rate

Active Ingredients

Borrelia Burgdorferi Bacterin

Administration Routes

SubcutaneousParenteralUnknownOther

Species Affected

Dog 475

Most Affected Breeds

Retriever - Labrador 76
Retriever - Golden 56
Shepherd Dog - German 33
Crossbred Canine/dog 20
Collie - Border 19
Shepherd Dog - Australian 18
Beagle 15
Mountain Dog - Bernese 12
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 9
Pit Bull 9

Most Reported Reactions

Lack of efficacy (bacteria) - Borrelia 270
Lack of efficacy (ectoparasite) - tick NOS 123
Other abnormal test result NOS 106
Lethargy (see also Central nervous system depression in 'Neurological') 28
Vomiting 25
Limping 24
Diarrhoea 22
Lack of efficacy (tick) 20
Lack of efficacy (bacteria) - NOS 20
Urine abnormalities NOS 16
Proteinuria 16
Lack of efficacy (bacteria) - Anaplasma 16

Outcome Breakdown

Outcome Unknown
357 (75.2%)
Ongoing
61 (12.8%)
Recovered/Normal
44 (9.3%)
Died
7 (1.5%)
Euthanized
6 (1.3%)

Data Summary

Metric Value
Total adverse event reports 475
Reports involving death 13
Case-fatality rate (reported events) 270.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Borrelia Burgdorferi Bacterin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 475 adverse event reports referencing Borrelia Burgdorferi Bacterin, including 13 reports in which the animal died — a 270.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Borrelia Burgdorferi Bacterin. Reported administration routes include Subcutaneous, Parenteral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Borrelia Burgdorferi Bacterin reports are Dog (475 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (76), Retriever - Golden (56), Shepherd Dog - German (33) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Borrelia Burgdorferi Bacterin are Lack of efficacy (bacteria) - Borrelia (270), Lack of efficacy (ectoparasite) - tick NOS (123), Other abnormal test result NOS (106), Lethargy (see also Central nervous system depression in 'Neurological') (28). Of the 475 reports with a coded outcome, Outcome Unknown is the leading category at 75.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Borrelia Burgdorferi Bacterin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial